Entera Bio Ltd. — Director's Dealing 2022

Sep 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Entera Bio Ltd. (ENTX)
CIK: 0001638097
Period of Report: 2022-09-07

Reporting Person: Toledano Miranda Jayne (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-07	Stock Option (right to buy)	$2.02	A	500000	Acquired	2032-05-16	Ordinary Shares, par value NIS 0.0000769 per share (500000)	Direct
2022-09-07	Stock Option (right to buy)	$1.40	A	600000	Acquired	2032-07-15	Ordinary Shares, par value NIS 0.0000769 per share (600000)	Direct

Footnotes

F1: This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 11, 2022, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on May 16, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

F2: This grant of options was approved by the Board on July 15, 2022, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on July 15, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.